| Bioactivity | BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis[1]. |
| CAS | 301357-87-9 |
| Formula | C26H21N5O3S |
| Molar Mass | 483.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Choi J, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2018, 28(6): 1116-1121. |
BMD4503-2
CAS: 301357-87-9 F: C26H21N5O3S W: 483.54
BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restore
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.